De Western Therapeutics Research Institute Inc.
Basic information
- Head office
- 18-11, Nishiki 1-chome, Naka-ku, Nagoya, Aichi Prefecture, Japan
- Chief executive
- Yuki Hidaka
- Capital
- 697,000,000 (6 100 million)
- Employees (non-consolidated)
- 19 people
- Employees (consolidated)
- 19 people
- Start date
- 1999-02-01
- End date
Websites
Business
Related companies
| Company name | Group | Parent | Subsidiary | Customer | Supplier | Alliance | Bank | Shareholder |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
Network
History
Established the De Western Therapeutics Research Institute Ltd. in Nagoya, Aichi Prefecture, for pharmaceutical research and development (capital 5,000 thousand yen).![]()
Established D.Western Therapeutics Institute, Inc. in Nagoya, Aichi Prefecture for the purpose of conducting pharmaceutical research and development (five million yen capitalization).![]()
Signed development and implementation agreements with Kowa Co., Ltd. for K-134 (occlusive atherosclerosis) and K-115 (glaucoma/ocular hypertension).![]()
Signed a development and implementation agreement with Kowa Co., Ltd. for K-115, a drug for treating glaucoma.![]()
Entered a joint research agreement with Mie University, a national university corporation, and established the "Clinical Drug Discovery Research Course" within the university.![]()
Entered into an industry-academia-government collaboration agreement with Mie University Faculty of Medicine for joint research, and jointly established Institute of Human Research Promotion and Drug Development at the University.![]()
Signed a contract granting re-implementation rights for the development, manufacturing, use, and sale of H-1129 (glaucoma/ocular hypertension) in Japan with Wakimoto Pharmaceutical Co., Ltd.![]()
Signed a contract granting exclusive implementation rights with re-implementation license for the development, manufacturing, use, and sale of H-1129 (glaucoma and ocular hypertension) in Japan by Wakimoto Pharmaceutical Co., Ltd.![]()
Obtained domestic manufacturing and sales approval for K-115 (product name: Granatac® eye drops 0.4%, generic name: Ripazil hydrochloride hydrate) for glaucoma/ocular hypertension.![]()
Domestic launch of Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension.![]()
GLANATEC® ophthalmic solution 0.4% (generic name: Ripasudil hydrochloride hydrate, K-115) for glaucoma launched in Japan.![]()
Signed an introduction agreement to obtain exclusive implementation rights for an ophthalmic therapeutic agent in Japan (development code: DW-1001).![]()
Signed an in-licensing agreement to acquire exclusive Japan license for an ophthalmic drug (DW-1001).![]()
Acquired the business related to an ophthalmic surgical adjunct containing BBG250 (development code: DW-1002).![]()
Commenced Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension), our first in-house developed product.![]()
Initiatied Phase I/IIa clinical trials of glaucoma treatment (H-1337), DWTI’s first in-house developed product, in the U.S.![]()
Signed a joint research and license agreement with Glaukos Corporation (USA) for glaucoma treatment products.![]()
Signed a joint research and licensing agreement with U.S.-based Glaukos Corporation for glaucoma drugs.![]()
Completed Phase I/early Phase II clinical trials in the United States for H-1337 (glaucoma/ocular hypertension).![]()
Obtained import approval for Granatac® eye drops 0.4% (development code: K-115) for glaucoma/ocular hypertension in South Korea.![]()
Submitted an IND application for a Phase II clinical trial in the United States targeting Fuchs endothelial corneal dystrophy with Ripazil hydrochloride hydrate (development code: K-321).![]()
Submitted an Investigational New Drug (IND) application for Phase II clinical trials in the U.S. of Ripasudil hydrochloride hydrate as treatment for Fuchs endothelial corneal dystrophy (K-321).![]()
Signed a license agreement with Lotte Pharmaceutical Co., Ltd. granting exclusive implementation rights for DW-1001 in Japan.![]()
Signed an agreement with Rohto Pharmaceutical Co., Ltd., granting exclusive Japan license for ophthalmic drug DW-1001.![]()
Start of Phase III clinical trial in Japan for a combination glaucoma treatment (Ripasudil hydrochloride hydrate and Brimonidine tartrate).![]()
Phase III clinical trials began in Japan for a fixed combination drug for treating glaucoma (Ripasudil hydrochloride hydrate and Brimonidine tartrate [K-232]).![]()
U.S. launch of DW-1002 (product name: TissueBlue™) (inner limiting membrane staining) and signing of a joint development agreement with Medrex Co., Ltd. for the neuropathic pain drug DW-5LBT.![]()
Addition of target diseases (corneal disorders, retinal diseases) for joint research with Glaukos Corporation in the U.S. and signing of a new license agreement.![]()
Added new disease types (corneal and retinal disorders) for joint research with U.S.-based Glaukos, and signed a new licensing agreement.![]()
Signed a joint development agreement with Actuare Co., Ltd. for the regenerative cell product DWR-2206 targeting vesicular keratitis.![]()
Signed a joint development agreement with ActualEyes Inc. for DWR-2206 regenerative cell therapy for bullous keratopathy.![]()
Initiated Phase III clinical trial of K-321 (Fuchs' corneal endothelial dystrophy) in the United States.![]()
Domestic launch of Gralla® combination eye drops (development code: K-232) (glaucoma and ocular hypertension) and start of Phase II late-stage U.S. clinical trial for H-1337 (glaucoma and ocular hypertension).![]()
GLA-ALPHA® combination ophthalmic solution (generic name: Ripasudil hydrochloride hydrate, brimonidine tartrate, K-232) for glaucoma and ocular hypertension launched in Japan.![]()
News
There is no news.
Public records
National Tax Agency basic information5180001055013
- Trade name
- 株式会社デ・ウエスタン・セラピテクス研究所
- Trade name (kana)
- デウエスタンセラピテクスケンキュウジョ
- Name in English
- Corporation type
- 301
- Address
- 〒460-0003 愛知県名古屋市中区錦1丁目18番11号
- Postal code
- 4600003
- Prefecture code
- 23
- City code
- 106
- Address outside Japan
- Prefecture in English
- City in English
- Address outside Japan in English
- Corporate number assignment date
- 2015-10-05
- Update date
- 2023-04-18
- Change date
- 2015-10-05
- Registry closure date
- Reason for registry closure
- Successor corporate number
- Details of the change
- Latest record
- 1
- Excluded from search
- 0
- Processing type
- 01
- Correction type
- 1
- Trade name image ID
- Address image ID
- Sequence number
- 3614749
METI gBizINFO5180001055013
- Corporate number
- 5180001055013
- Trade name
- 株式会社デ・ウエスタン・セラピテクス研究所
- Trade name (kana)
- デウエスタンセラピテクスケンキュウジョ
- Trade name (alphabet)
- Registry closure date
- Reason for registry closure
- Registered address
- 愛知県名古屋市中区錦1丁目18番11号
- Postal code
- 4600003
- Prefecture
- 愛知県
- Prefecture code
- 23
- City or district
- 名古屋市中区
- City code
- 106
- Street address
- 錦1丁目18番11号
- Organisation type
- 301
- Processing type
- 01
- Correction type
- 1
- Status
- Representative
- 代表取締役社長 日高 有一
- Capital
- 697340000
- Employees
- 19
- Employees (male)
- Employees (female)
- Business summary
- Website URL
- Year founded
- Business category
- Date established
- Unified government qualification - grade
- Unified government qualification - business items
- Update date
- 2023-04-18
- Key information
- 5180001055013